Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of PER-001 in Participants With Open-Angle Glaucoma
Sponsor: Perfuse Therapeutics, Inc.
Summary
This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.
Official title: A Phase 1/2a Study to Evaluate Safety, Tolerability, and Pharmacodynamic Effect After Single Administration of PER-001 Intravitreal Implant in Participants With Open-Angle Glaucoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2023-05-25
Completion Date
2026-04-04
Last Updated
2025-04-15
Healthy Volunteers
No
Conditions
Interventions
PER-001 Intravitreal Implant - Low Dose
PER-001 Low Dose Intravitreal Implant
PER-001 Intravitreal Implant - High Dose
PER-001 High Dose Intravitreal Implant
PER-001 Intravitreal Implant - Sham
PER-001 Intravitreal Sham
Locations (1)
Perfuse Therapeutics, Inc.
San Francisco, California, United States